Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-23-026831
Filing Date
2023-02-28
Accepted
2023-02-28 17:26:42
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm238017d3_defa14a.htm DEFA14A 24645
  Complete submission text file 0001104659-23-026831.txt   25657
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36033 | Film No.: 23687556
SIC: 2834 Pharmaceutical Preparations